{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:34:21Z","timestamp":1780569261812,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["20204Y0176"],"award-info":[{"award-number":["20204Y0176"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jphs.2023.12.011","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T12:17:21Z","timestamp":1703852241000},"page":"113-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Farrerol suppresses osteoclast differentiation and postmenopausal osteoporosis by inhibiting the nuclear factor kappa B signaling pathway"],"prefix":"10.1016","volume":"154","author":[{"given":"Wei","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Defang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingmin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengxin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2023.12.011_bib1","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1359\/jbmr.2001.16.5.901","article-title":"Classification of osteoporosis based on bone mineral densities","volume":"16","author":"Lu","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jphs.2023.12.011_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF01623184","article-title":"Hip fractures in the elderly: a world-wide projection","volume":"2","author":"Cooper","year":"1992","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jphs.2023.12.011_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European union: medical management, epidemiology and economic burden. A report prepared in collaboration with the international osteoporosis foundation (IOF) and the European federation of pharmaceutical industry associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch Osteoporosis"},{"key":"10.1016\/j.jphs.2023.12.011_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","article-title":"An overview and management of osteoporosis","volume":"4","author":"Sozen","year":"2017","journal-title":"European journal of rheumatology"},{"key":"10.1016\/j.jphs.2023.12.011_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1034\/j.1601-0825.2002.01829.x","article-title":"Regulatory mechanisms of osteoblast and osteoclast differentiation","volume":"8","author":"Katagiri","year":"2002","journal-title":"Oral Dis"},{"key":"10.1016\/j.jphs.2023.12.011_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4248\/BR201301005","article-title":"Bone remodeling and energy metabolism: new perspectives","volume":"1","author":"de Paula","year":"2013","journal-title":"Bone research"},{"key":"10.1016\/j.jphs.2023.12.011_bib7","first-page":"92","article-title":"Osteoporosis: a review of treatment options","volume":"43","author":"Tu","year":"2018","journal-title":"P & T : a peer-reviewed journal for formulary management"},{"key":"10.1016\/j.jphs.2023.12.011_bib8","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/bcp.13759","article-title":"Side effects of drugs for osteoporosis and metastatic bone disease","volume":"85","author":"Skjodt","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jphs.2023.12.011_bib9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1517\/14740338.2016.1136287","article-title":"Safety issues and adverse reactions with osteoporosis management","volume":"15","author":"Rossini","year":"2016","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.jphs.2023.12.011_bib10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/15216540500137669","article-title":"RANKing intracellular signaling in osteoclasts","volume":"57","author":"Feng","year":"2005","journal-title":"IUBMB Life"},{"key":"10.1016\/j.jphs.2023.12.011_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115316","article-title":"A novel inhibitor of NF-kappaB-inducing kinase prevents bone loss by inhibiting osteoclastic bone resorption in ovariectomized mice","volume":"135","author":"Takakura","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.jphs.2023.12.011_bib12","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s00198-013-2313-x","article-title":"NF-kappaB signaling and bone resorption","volume":"24","author":"Abu-Amer","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jphs.2023.12.011_bib13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri.2017.52","article-title":"The non-canonical NF-kappaB pathway in immunity and inflammation","volume":"17","author":"Sun","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jphs.2023.12.011_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121636","article-title":"The role of NF-kappaB in physiological bone development and inflammatory bone diseases: is NF-kappaB inhibition \"killing two birds with one stone\"?","volume":"8","author":"Jimi","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jphs.2023.12.011_bib15","doi-asserted-by":"crossref","first-page":"16229","DOI":"10.1039\/D0NR02848G","article-title":"Chitosan derived nitrogen-doped carbon dots suppress osteoclastic osteolysis via downregulating ROS","volume":"12","author":"Chen","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.jphs.2023.12.011_bib16","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1182\/blood-2004-09-3662","article-title":"A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation","volume":"106","author":"Lee","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jphs.2023.12.011_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20143576","article-title":"Reactive oxygen species in osteoclast differentiation and possible pharmaceutical targets of ROS-mediated osteoclast diseases","volume":"20","author":"Agidigbi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jphs.2023.12.011_bib18","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s11033-020-06128-5","article-title":"Signaling pathways in human osteoclasts differentiation: ERK1\/2 as a key player","volume":"48","author":"Pennanen","year":"2021","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.jphs.2023.12.011_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/13880209.2021.2006723","article-title":"The pharmacological properties and corresponding mechanisms of farrerol: a comprehensive review","volume":"60","author":"Qin","year":"2022","journal-title":"Pharm Biol"},{"key":"10.1016\/j.jphs.2023.12.011_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24193470","article-title":"A complete study of farrerol metabolites produced in vivo and in vitro","volume":"24","author":"Yin","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.jphs.2023.12.011_bib21","article-title":"Farrerol relieve lipopolysaccharide (LPS)-Induced mastitis by inhibiting AKT\/NF-kappaB p65, ERK1\/2 and P38 signaling pathway","volume":"19","author":"Li","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jphs.2023.12.011_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105739","article-title":"Farrerol protects dopaminergic neurons in a rat model of lipopolysaccharide-induced Parkinson's disease by suppressing the activation of the AKT and NF-kappaB signaling pathways","volume":"75","author":"Li","year":"2019","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.jphs.2023.12.011_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19072037","article-title":"Farrerol ameliorates TNBS-induced colonic inflammation by inhibiting ERK1\/2, JNK1\/2, and NF-kappaB signaling pathway","volume":"19","author":"Ran","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jphs.2023.12.011_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/jfbc.13585","article-title":"Farrerol ameliorate adjuvant-induced ankle injury via alteration of PPAR-gamma signal pathway","volume":"45","author":"Tian","year":"2021","journal-title":"J Food Biochem"},{"key":"10.1016\/j.jphs.2023.12.011_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4068\/cmj.2016.52.1.12","article-title":"Signaling pathways in osteoclast differentiation","volume":"52","author":"Kim","year":"2016","journal-title":"Chonnam Med J"},{"key":"10.1016\/j.jphs.2023.12.011_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.772540","article-title":"BCI suppresses RANKL-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss","volume":"12","author":"Cai","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jphs.2023.12.011_bib27","series-title":"Iron Overload-Induced Ferroptosis of Osteoblasts Inhibits Osteogenesis and Promotes Osteoporosis: An in Vitro and in Vivo Study","author":"Jiang","year":"2022"},{"key":"10.1016\/j.jphs.2023.12.011_bib28","article-title":"\u03b1-Asarone attenuates osteoclastogenesis and prevents against oestrogen-deficiency induced osteoporosis","volume":"13","author":"Tian","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jphs.2023.12.011_bib29","article-title":"Cycloastragenol attenuates osteoclastogenesis and bone loss by targeting RANKL-induced nrf2\/keap1\/ARE, NF-\u03baB, calcium, and NFATc1 pathways","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jphs.2023.12.011_bib30","article-title":"Asiatic acid attenuates osteoporotic bone loss in ovariectomized mice through inhibiting NF-kappaB\/MAPK\/protein kinase B signaling pathway","volume":"13","author":"Dong","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jphs.2023.12.011_bib31","article-title":"Alpha-asarone attenuates osteoclastogenesis and prevents against oestrogen-deficiency induced osteoporosis","volume":"13","author":"Tian","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jphs.2023.12.011_bib32","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3389\/fphys.2019.01419","article-title":"Farrerol attenuates cisplatin-induced nephrotoxicity by inhibiting the reactive oxygen species-mediated oxidation, inflammation, and apoptotic signaling pathways","volume":"10","author":"Ma","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.jphs.2023.12.011_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/jfbc.13585","article-title":"Farrerol ameliorate adjuvant-induced ankle injury via alteration of PPAR-\u03b3 signal pathway","volume":"45","author":"Tian","year":"2021","journal-title":"J Food Biochem"},{"key":"10.1016\/j.jphs.2023.12.011_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15563-7","article-title":"Catabolic effects of human PTH (1-34) on bone: requirement of monocyte chemoattractant protein-1 in murine model of hyperparathyroidism","volume":"7","author":"Siddiqui","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jphs.2023.12.011_bib35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.11005\/jbm.2014.21.4.233","article-title":"Regulation of NFATc1 in osteoclast differentiation","volume":"21","author":"Kim","year":"2014","journal-title":"J Bone Metab"},{"key":"10.1016\/j.jphs.2023.12.011_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00774-020-01191-1","article-title":"RANKL as the master regulator of osteoclast differentiation","volume":"39","author":"Takayanagi","year":"2021","journal-title":"J Bone Miner Metabol"},{"key":"10.1016\/j.jphs.2023.12.011_bib37","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1084\/jem.20051150","article-title":"Autoamplification of NFATc1 expression determines its essential role in bone homeostasis","volume":"202","author":"Asagiri","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jphs.2023.12.011_bib38","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/360741a0","article-title":"Bone and haematopoietic defects in mice lacking c-fos","volume":"360","author":"Wang","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.jphs.2023.12.011_bib39","doi-asserted-by":"crossref","first-page":"18245","DOI":"10.1074\/jbc.M610701200","article-title":"NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1","volume":"282","author":"Yamashita","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jphs.2023.12.011_bib40","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1359\/JBMR.041213","article-title":"Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1","volume":"20","author":"Takatsuna","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jphs.2023.12.011_bib41","article-title":"Chrysin protects against titanium particle-induced osteolysis by attenuating osteoclast formation and function by inhibiting NF-\u03baB and MAPK signaling","volume":"13","author":"Wu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jphs.2023.12.011_bib42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1302\/2046-3758.114.BJR-2020-0308.R2","article-title":"N,N-Dimethylformamide inhibits high glucose-induced osteoporosis via attenuating MAPK and NF-\u03baB signalling","volume":"11","author":"Liu","year":"2022","journal-title":"Bone & Joint Res."},{"key":"10.1016\/j.jphs.2023.12.011_bib43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cytogfr.2008.11.007","article-title":"NF-kappaB modulators in osteolytic bone diseases","volume":"20","author":"Xu","year":"2009","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jphs.2023.12.011_bib44","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2174\/1389450118666170321105425","article-title":"Therapeutic potential and outlook of alternative medicine for osteoporosis","volume":"18","author":"Wang","year":"2017","journal-title":"Curr Drug Targets"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861323000798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861323000798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:04:20Z","timestamp":1761163460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861323000798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1347861323000798"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2023.12.011","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Farrerol suppresses osteoclast differentiation and postmenopausal osteoporosis by inhibiting the nuclear factor kappa B signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2023.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}